Halozyme Therapeutics, Inc. (HALO) 2022年年度报告「NASDAQ」.pdf

1、Annual Report20222022 was a tr ansfor mative year for Halozyme.We deliver ed r ecor d r evenue fr om our ENHANZE business and ext ended our drug delivery leadership and expanded our commer cial portfolio with the acquisition of Antar es Phar ma.We had many successes and lear nings this year and t og

2、ether,as One Team,we demonstr at ed oper ational excellence thr oughout the or ganization for the benefit of patients ar ound the wor ld.Halozymes successes wer e mar ked by str ong gr owth in r evenue and pr ofits as we str engthened our partnerships and enhanced our capabilities t o support cur r

3、ent and new partners with ENHANZE and an innovative aut o-inject or t echnology platfor m.All of this and mor e,delivers on our commitment t o our stakeholders,including our shar eholders.RECORD GROWTH FOR HALOZYME Our str ong perfor mance acr oss the business,including the successful int egr ation

4、of Antar es Phar ma,dr ove another year of r ecor d r evenue,with$660.1 million,r epr esenting 49%year-over-year gr owth.Revenue fr om r oyalties in 2022 also achieved r ecor d levels,incr easing 77%t o$360.5 million,pr imar ily dr iven by str ong adoption of our ENHANZE partner pr oducts DARZALEX F

5、aspr o and Phesgo and the addition of the aut o-inject or r oyalt y r evenue.Our leadership in drug delivery with a commer cial portfolio has augment ed our gr owth pot ential,diversified our r evenue str eams and ext ended our r evenue dur abilit y.We look forwar d t o further str engthening our po

6、sition as the drug delivery partner of choice for phar maceutical and biot echnology companies with ENHANZE and our aut o-inject or t echnology platfor ms.PARTNER SUCCESS WITH ENHANZEWith an established leadership in drug delivery,we have five globally-appr oved partner pr oducts utilizing ENHANZE a